If FCR will be the procedure of decision, caution need to be taken in individuals with NOTCH1 mutations, in whom rituximab seems to acquire minor additional worth.59 Other genomic subgroups, including people with BIRC3 mutations look to derive little gain from CIT,111,112 but these results need to be more validated. https://anthonyi218dls5.blogsidea.com/profile